硬脊膜的蠕变率与椎间盘突出症的自然病程

目的　为探讨椎间盘突出症缓慢自愈的机理和治疗方法的选择提供一定的帮助。方法　应用２１ 例新鲜的猪的腰段硬脊膜,分组测量其蠕变率的变化。结果　各组蠕变率均与时间和载荷成正比,控温组发生速度快而大,模拟组发生慢而小。结论　蠕变率是椎间盘突出症症状缓解的力学基础,促进蠕变率发生的治疗,同减压治疗一样,都是病因治疗。     

无毛KM小鼠近交培育的阶段性成果

将本部发现的一只无毛ＫＭ小鼠进行回交和自交后,自１９９５年２月起采取全同胞兄妹交配的方法,培育至今已达Ｆ１８。代间隔平均为７１．５ｄ（５５～１１６ｄ）。以近交Ｆ１８与ＤＢＡ／２交配进行毛色基因测试,其杂交１代毛色一致,提示Ｆ１８无毛小鼠已达到较高的基因纯合度。该无毛小鼠自４周龄起全身开始脱毛,至５周龄全身基本无毛,６周龄后又长出稀短的毛。该鼠已经剖宫取胎净化为清洁级。     

大剂量干扰素治疗慢性丙型肝炎50例临床观察

目的：探讨使用大剂量干扰素（ＩＦＮα）治疗慢性丙型肝炎（ＣＡＨ）的效果。方法：使用大剂量ＩＦＮα,每天６００万Ｕ,连续投药３周,以后每周３次间断投药２１周,共计２４周,治疗ＣＡＨ５０例。观察治疗前后血清ＨＣＶＲＮＡ与ＡＬＴ的变化,以此作为ＩＦＮ疗效的判定指标。结果：ＩＦＮ治疗ＣＡＨ有效率为６８％,停药６个月后有３４％复发。结论：ＩＦＮ的疗效与ＣＡＨ的基因亚型有关（Ⅲ型疗效显著,Ⅱ型较差）,与ＩＦＮ的剂量无明显关系。     

颞肌筋膜瓣在上颌骨缺损修复中的应用

目的与方法：本文总结了颞肌筋膜瓣修复上颌骨缺损２０例经验。其中上颌骨全部切除９例,上颌骨扩大切除３例,上颌骨部分切除８例。结果与结论：颞肌筋膜瓣全部成活,口腔内无覆盖的颞肌筋膜瓣发生上皮化。２例术后出现轻度张口受限外,未发现其它并发症,作者对颞肌筋膜剖要点及手术方法进行了描术,并对颞肌膜瓣的优点及注意事项进行了讨论。     

银杏叶提取物对兔心肌缺血再灌注损伤时中性粒细胞活化的影响

目的 观察兔心肌缺血再灌注前后ＰＭＮ（中性粒细胞）的活性变化过程。了解银杏叶提取物保护心肌是否与影响中性粒细胞活化作用有关。方法 取３０只日本大耳白兔随机均分为３组,假手术对照组、缺血再灌注组和实验用药组。用药方法：用自制的银杏叶提取物注射剂（总黄酮含量５ｍｇ／ｍｌ）５ｍｌ静滴给药。分别于冠脉结扎前和结扎缺血１ｈ后采血用布式显微镜观察白细胞活化状态的变化。检测白细胞表面粘附分子ＣＤ１１／ＣＤ１８表     

Bcl-2 和p53 蛋白表达对肝硬变和肝细胞癌中细胞增殖和凋亡的调节

利用原位 Ｄ Ｎ Ａ 末端转移酶标记技术及 Ｓ Ｐ 免疫组织化学方法检测了肝硬变和肝细胞癌（ Ｈ Ｃ Ｃ）组织中凋亡细胞,ｐ５３ , ｂｃｌ２ 蛋白和 Ｐ Ｃ Ｎ Ａ 的表达。结果显示： Ｈ Ｃ Ｃ 与肝硬变组织比较,凋亡细胞密度低, Ｐ Ｃ Ｎ Ａ 阳性细胞密度高,ｐ５３ 和 ｂｃｌ２ 蛋白阳性强度高,且均与 Ｈ Ｃ Ｃ 分化程度有关。提示ｐ５３ 和 ｂｃｌ２ 蛋白可能是通过其过度表达影响细胞增殖和细胞凋亡失衡,并以“选择性细胞增殖”形式导致 Ｈ Ｃ Ｃ 的发生和发展。     

Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3

BACKGROUND: Exposure of prostate carcinoma cell lines to retinoids, which function through the classical retinoic acid nuclear receptor, (RARs) or retinoid X receptors (RXRs), results in minimal cytostatic inhibition of cell proliferation. METHODS: Growth inhibition and various regulatory responses were investigated in two human prostate carcinoma cell lines (LNCaP and PC-3) treated with or without a synthetic retinoid, CD 437. RESULTS: Incubation of prostate carcinoma cell lines with a novel retinoid CD437 resulted in the marked inhibition of proliferation. LNCaP and PC-3 possessed IC50 values for CD437 of 375 nM and 550 nM, respectively. Incubation with 1 microM CD437 for 24 hr resulted in 100% and 60% inhibition of growth in LNCaP and PC-3 cells, respectively. Simultaneously, cell flow cytometric analyses revealed a dramatic increase of the cell population in S phase, in both LNCaP (from 38.6% up to 86.7%) and PC-3 (27.9% to 55.7%), and a decreased proportion of cells in G2 phase, in LNCaP (from 23.7% down to 1.2%) and PC-3 (14.9% to 2.2%), indicating a significant S-phase arrest. The cell growth inhibition and S-phase arrest in these cells were followed by apoptosis, as revealed by the acquisition of the characteristic cell morphology including the appearance of apoptotic bodies, and further confirmed by cellular DNA fragmentation. CD437-induced-S phase arrest was associated with upregulated mRNA levels of p21waf1/cip1/sdi1 in both LNCaP (p53+/+) and PC-3 (53-/-) cells. CONCLUSIONS: CD437 represents a unique retinoid that induces S-phase arrest and apoptosis in both androgen-dependent (LNCaP) and -independent (PC-3) human prostate cancer cells, suggesting a potential role of CD437 in the treatment of human prostate cancer.     

直肠癌癌旁移行粘膜MTS1基因产物表达的意义

目的 探讨直肠癌癌旁移行粘膜（ＴＭ）的性质及多种种瘤抑制基因（ＭＴＳ１）基因缺失的临床意义。方法 应用粘液组化方法观察了直肠癌旁ＴＭ的范围,免疫组化方法观察了ＭＴＳ１基因产物表达情况,并与正常粘膜及癌组织进行对照 结果 ＭＴＳ１基因产物在正常直肠膜阳性表达率最高,在癌旁ＴＭ、癌组织表达逐渐减少,三者差异有显著意义（Ｐ〈０．０５）;ＭＴＳ１阴性的直肠癌病例,癌旁ＴＭ的明显高于ＭＴＳ１阳性的病例（Ｐ〉     

Performance of the Frameless IUD (Flexigard prototype inserter) and the TCu380A after six years as part of a WHO multicenter randomized comparative clinical trial in parous women

The clinical performance of the new Frameless IUD was compared with the TCu380A, the most widely used copper IUD in the world today. Insertions of the Frameless IUD were conducted with a prototype inserter (Flexigard). We report on the 6-year results from a randomized comparative clinical trial conducted at the Shanghai Institute of Planned Parenthood Research, as part of an international multicenter WHO clinical trial, involving 200 women, respectively recruited for use of each device. The cumulative 6-year pregnancy rates were 0.0 per 100 women for the Frameless IUD and 3.3 for TCu380A. Termination due to partial expulsion was significantly less for the Frameless IUD as compared with TCu380A (0.0 and 4.3 per hundred women, respectively). Complete expulsion, bleeding, pain, bleeding and pain and other medical reasons for termination did not differ significantly between the two devices. The net cumulative continuation rates at six years per 100 women were 80.8 for TCu380A, and 83.0 for the Frameless IUD.Both Frameless IUD and TCu380A are highly effective, safe and acceptable contraceptive devices, because of low pregnancy rates (per 100 women), and low termination rates due to expulsion, pain, bleeding, and bleeding and pain. Due to its anchoring, the Frameless IUD is significantly more effective than the TCu380A IUD as regards proper retention of the IUD in the uterine cavity. This may also explain its lower failure rate.